Digoxin immune fab: Difference between revisions

Jump to navigation Jump to search
m (Gerald Chi moved page Digoxin Immune Fab to Digoxin immune fab)
(No difference)

Revision as of 16:46, 4 July 2014

Digoxin Immune Fab
DIGIFAB® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Digoxin Immune Fab
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

For patient information about Digoxin immune fab, click here.

Synonyms / Brand Names: DIGIFAB ® injection

Overview

Digoxin Immune Fab (Ovine) is the generic name for an antidote for overdose of digitalis.[1] It is made from immunoglobin fragments from sheep who have already been immunized with a digoxin derivative, digoxindicarboxymethoxylamine (DDMA). Its brand names include Digibind and DigiFab, with the former manufactured by GlaxoSmithKline and the latter manufactured by Protherics, Inc.

Category

Digitalis antidote.

FDA Package Insert

DIGIFAB®

Indications and Usage | Dosage and Administration | Contraindications | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

DigiFab has an affinity for digoxin in the range of 109 to 1010 M-1, which is greater than the affinity of digoxin for its sodium pump receptor, the presumed receptor for its therapeutic and toxic effects. When administered to the intoxicated patient, DigiFab binds to molecules of digoxin reducing free digoxin levels, which results in a shift in the equilibrium away from binding to the receptors, thereby reducing cardio-toxic effects. Fab-digoxin complexes are then cleared by the kidney and reticuloendothelial system.

References

  1. DiDomenico RJ, Walton SM, Sanoski CA, Bauman JL (2000). "Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity". J. Cardiovasc. Pharmacol. Ther. 5 (2): 77–85. PMID 11150387.

http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6832767f-db6b-4eea-b88b-bdfc905749e1